Mylan Inc. May 17 announced that its subsidiary, Mylan Pharmaceuticals Inc., has received final approval from the Food and Drug Administration for its generic version of AbbVie Inc.'s Tricor (fenofibrate) 48 mg and 145 mg tablets.
Tricor is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides, and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adults with primary hypercholesterolemia or mixed dyslipidemia.
The product also is indicated as adjunctive therapy to diet for adults with severe hypertriglyceridemia.
Mylan, which is based in Pittsburgh, said it has shipped ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.